| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5581692 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 25 Pages |
Abstract
Further evaluation of PLD, bortezomib, and deacetylase inhibitor combinations is warranted, with special attention directed toward strategies to improve tolerability.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Peter M. Voorhees, Cristina Gasparetto, Dominic T. Moore, Diane Winans, Robert Z. Orlowski, David D. Hurd,